| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------|-------|-------|-------------|-------|-------|--------|-------|-------|-----------|-------|--------| | | Q1 | Q2 | 2022 \nQ3 | Q4 | | FY | Q1 | Q2 | 2023 \nQ3 | Q4 | FY | | Including COVID-19 solutions | | | | | | | | | | | | | Sales (£m) | 7,190 | 6,929 | 7,829 | 7,376 | | 29,324 | 6,951 | 7,178 | 8,147 | 8,052 | 30,328 | | Operating profit (£m) | 1,943 | 2,008 | 2,605 | 1,595 | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form ...

Meet GSK management Getting ahead of respiratory diseases Interactive event for investors and analysts. This webinar is being recorded. gsk.com This presentation may contain forward-looking statements. Forward-looking statements qive the Group's current expectations or forecosts of future events. An investor con i statements by the fact that they do not relate strictly to historical or current focts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'belie other words and tems of ...

Company Participants Conference Call Participants Nick Stone The presentation was sent out to our distribution list by email. And you can also find us on gsk.com. Please turn to Slide 3. Today's call will last approximately one hour with the management presentation taking around 30 minutes and the remaining time for your questions. [Operator Instructions] I'll now hand the call over to Emma. Thanks, Nick, and welcome to everybody joining us today. Sales and profits grew double-digits for the quarter, with s ...

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or For ...

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Rep ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40 ...

Summary of GSK plc Conference Call Company Overview - **Company**: GSK plc (NYSE:GSK) - **Event**: Goldman Sachs 44th Annual Global Healthcare Conference Call - **Date**: June 13, 2023 - **Participants**: Tony Wood (Chief Scientific Officer), Chris Shibutani (Goldman Sachs) Key Points Industry Focus - GSK is focusing on several therapeutic areas: infectious diseases, HIV, immunology, respiratory, and oncology [5][6][9] R&D Strategy - GSK has identified a strong position in vaccines, particularly in protein subunit vaccines and adjuvants, and is investing in technologies like structure-based vaccinology and mRNA [6][7][8] - The acquisition of Affinivax is aimed at entering the pneumococcal vaccine market, which is the second largest after COVID vaccines [7] - GSK is developing capabilities in mRNA technology through collaboration with CureVac, focusing on high-dose flu and COVID vaccines [8] Vaccine Development - GSK is competitive in the high-dose flu and COVID vaccine market but acknowledges being slightly behind in timing compared to competitors like Moderna [11] - The company is conducting multivalent flu studies to establish a presence in the high-dose flu market [11] - GSK's RSV vaccine has shown a 94% efficacy in at-risk populations, with ongoing studies to expand data for older adults [15][17] HIV Treatment and PrEP - GSK's strategy in HIV focuses on long-acting regimens and the integration of cabotegravir, which has strong resistance characteristics [25][26] - The market for PrEP is underpenetrated, with only 25% of eligible patients receiving treatment in the U.S. [29] Competitive Landscape - GSK's Shingrix vaccine offers 10-12 years of protection, presenting a high barrier for new entrants [32] - In the meningococcal vaccine space, GSK emphasizes the importance of vaccine efficacy and strain coverage compared to competitors [34] Antibiotics and Oncology - GSK continues to explore opportunities in antibiotics despite challenges, focusing on acquisitions that can make economic sense [39] - Oncology remains an area of interest, with ongoing evaluations of existing products and potential new deals [41] Future Outlook - GSK is preparing for the 2023 vaccine season and is confident in its manufacturing capabilities [19] - The company is exploring expansion into different age groups for its vaccines but does not plan to revisit maternal vaccines at this time [21] Additional Insights - GSK is focused on the balance between vaccine efficacy and convenience in the context of combination vaccines [23] - The company is monitoring the competitive landscape closely, particularly in the context of emerging technologies and products from competitors [41] This summary encapsulates the critical insights from the GSK conference call, highlighting the company's strategic focus, competitive positioning, and future outlook in the healthcare industry.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F . . . .X. . . . Form 40-F . . . . . . . . Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number 001-15170 GSK plc (Translation of registrant's name into English) 980 Great West Road, Brentford, Mi ...